TORRANCE, Calif., June 26, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it has received Food and Drug Administration ...
Emmaus Life Sciences has entered into an agreement to sell the North American rights to its oral sickle cell disease treatment Endari.
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, marketing, and sale of innovative treatments and therapies, including those for rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback